The use of non-steroidal anti-inflammatory drugs (NSAIDs) in COVID-19.

IF 3.1 3区医学 Q1 PRIMARY HEALTH CARE

NPJ Primary Care Respiratory Medicine Pub Date : 2022-09-21 DOI:10.1038/s41533-022-00300-z

Pamela Kushner, Bill H McCarberg, Laurent Grange, Anton Kolosov, Anela Lihic Haveric, Vincent Zucal, Richard Petruschke, Stephane Bissonnette

{"title":"The use of non-steroidal anti-inflammatory drugs (NSAIDs) in COVID-19.","authors":"Pamela Kushner, Bill H McCarberg, Laurent Grange, Anton Kolosov, Anela Lihic Haveric, Vincent Zucal, Richard Petruschke, Stephane Bissonnette","doi":"10.1038/s41533-022-00300-z","DOIUrl":null,"url":null,"abstract":"<p><p>Early in the COVID-19 pandemic, anecdotal reports emerged suggesting non-steroidal anti-inflammatory drugs (NSAIDs) may increase susceptibility to infection and adversely impact clinical outcomes. This narrative literature review (March 2020-July 2021) attempted to clarify the relationship between NSAID use and COVID-19 outcomes related to disease susceptibility or severity. Twenty-four relevant publications (covering 25 studies) reporting original research data were identified; all were observational cohort studies, and eight were described as retrospective. Overall, these studies are consistent in showing that NSAIDs neither increase the likelihood of SARS-CoV-2 infection nor worsen outcomes in patients with COVID-19. This is reflected in current recommendations from major public health authorities across the world, which support NSAID use for analgesic or antipyretic treatment during COVID-19. Thus, there is no basis on which to restrict or prohibit use of these drugs by consumers or patients to manage their health conditions and symptoms during the pandemic.</p>","PeriodicalId":19470,"journal":{"name":"NPJ Primary Care Respiratory Medicine","volume":null,"pages":null},"PeriodicalIF":3.1000,"publicationDate":"2022-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489480/pdf/","citationCount":"17","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"NPJ Primary Care Respiratory Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41533-022-00300-z","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PRIMARY HEALTH CARE","Score":null,"Total":0}

引用次数: 17

Abstract

Early in the COVID-19 pandemic, anecdotal reports emerged suggesting non-steroidal anti-inflammatory drugs (NSAIDs) may increase susceptibility to infection and adversely impact clinical outcomes. This narrative literature review (March 2020-July 2021) attempted to clarify the relationship between NSAID use and COVID-19 outcomes related to disease susceptibility or severity. Twenty-four relevant publications (covering 25 studies) reporting original research data were identified; all were observational cohort studies, and eight were described as retrospective. Overall, these studies are consistent in showing that NSAIDs neither increase the likelihood of SARS-CoV-2 infection nor worsen outcomes in patients with COVID-19. This is reflected in current recommendations from major public health authorities across the world, which support NSAID use for analgesic or antipyretic treatment during COVID-19. Thus, there is no basis on which to restrict or prohibit use of these drugs by consumers or patients to manage their health conditions and symptoms during the pandemic.

查看原文本刊更多论文

在COVID-19中使用非甾体抗炎药(NSAIDs)。

在COVID-19大流行早期，坊间报道表明，非甾体抗炎药(NSAIDs)可能增加感染易感性，并对临床结果产生不利影响。这篇叙述性文献综述(2020年3月- 2021年7月)试图澄清非甾体抗炎药使用与疾病易感性或严重程度相关的COVID-19结局之间的关系。确定了24篇报道原始研究数据的相关出版物(涵盖25项研究);所有研究均为观察性队列研究，其中8项为回顾性研究。总体而言，这些研究一致表明，非甾体抗炎药既不会增加COVID-19患者感染SARS-CoV-2的可能性，也不会恶化预后。这反映在世界各地主要公共卫生当局目前的建议中，这些建议支持在COVID-19期间使用非甾体抗炎药进行镇痛或解热治疗。因此，没有根据限制或禁止消费者或患者在大流行期间使用这些药物来控制其健康状况和症状。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

NPJ Primary Care Respiratory Medicine PRIMARY HEALTH CARE-RESPIRATORY SYSTEM

CiteScore

5.50

自引率

6.50%

发文量

审稿时长

10 weeks

期刊介绍： npj Primary Care Respiratory Medicine is an open access, online-only, multidisciplinary journal dedicated to publishing high-quality research in all areas of the primary care management of respiratory and respiratory-related allergic diseases. Papers published by the journal represent important advances of significance to specialists within the fields of primary care and respiratory medicine. We are particularly interested in receiving papers in relation to the following aspects of respiratory medicine, respiratory-related allergic diseases and tobacco control: epidemiology prevention clinical care service delivery and organisation of healthcare (including implementation science) global health.